Speed of Response in Biologic Treatments for Moderate-to-Severe Plaque Psoriasis: Bayesian Network Meta-Analysis

Authors

• Zaid Shami, HCA Aventura Hospital and Medical Center, Miami, FL
• Shivkar Amara, Northwell Long Island Jewish Medical Center, Queens, NY
• Stephanie V. Shimon, HCA Aventura Hospital and Medical Center, Miami, FL
• Isabella Kest, Albert Einstein College of Medicine, New York, NY
• Rahib K. Islam, LSU Health Sciences Center - New OrleansFollow
• Luciano Moffatt, Universidad de Buenos Aires, Buenos Aires, Argentina
• Mark Lebwohl, Icahn School of Medicine at Mount Sinai, New York, NY

Document Type

Article

Publication Date

8-1-2026

Publication Title

Journal of Drugs in Dermatology

Abstract

Background: Psoriasis is a chronic inflammatory condition affecting approximately 3% of adults in the United States (US). While biologic therapies have transformed treatment for psoriasis, the speed and efficacy of response vary among biologics. This network meta-analysis (NMA) evaluates the efficacy and speed of response of interleukin (IL)-17 and IL-23, and tumor necrosis factor-alpha (TNF-alpha) inhibitors during the first 8 weeks of treating moderate-to-severe plaque psoriasis. Methods: This Bayesian NMA used data from 53 phase 2b and 3 randomized controlled trials (RCTs). Efficacy was measured by Psoriasis Area and Severity Index (PASI) 75, PASI 90, and PASI 100 (≥75%, ≥90%, and 100% reduction in PASI score) at weeks 4 and 8. Absolute differences (absolute response minus placebo; AD) were calculated using a random-effects model. Results: IL-17 inhibitors, specifically brodalumab, bimekizumab, and ixekizumab, had the highest AD in PASI 75, PASI 90, and PASI 100 at week 4 and week 8. Do Not Copy Discussion/Conclusion: IL-17 inhibitors, specifically bimekizumab,Penaltiesbrodalumab,Apply and ixekizumab, had a higher percentage of patients (measured as absolute difference in this study), achieving PASI 75, PASI 90, and PASI 100 at week 4 and week 8. However, there was no significant difference in absolute difference for the same endpoints and time points for patients treated with brodalumab, bimekizumab, and ixekizumab. IL-23 inhibitors, while effective, exhibited a slower onset; TNF-alpha inhibitors, except infliximab, generally showed slower responses. Indirect comparisons and differences in study design and populations may limit the generalizability of the results.

First Page

686

Last Page

694

PubMed ID

42555067

Volume

25

Issue

8

Rights

© 2026 Journal of Drugs in Dermatology

Recommended Citation

Shami, Zaid; Amara, Shivkar; Shimon, Stephanie V.; Kest, Isabella; Islam, Rahib K.; Moffatt, Luciano; and Lebwohl, Mark, "Speed of Response in Biologic Treatments for Moderate-to-Severe Plaque Psoriasis: Bayesian Network Meta-Analysis" (2026). School of Medicine Faculty Publications. 4998.
https://digitalscholar.lsuhsc.edu/som_facpubs/4998
10.36849/JDD.10111